Based on market forecasts, the chronic obstructive pulmonary disease sector will expand from USD 23.55 billion in 2025 to USD 36.29 billion by 2035, experiencing a CAGR of 4.42%. In 2025, North America led the COPD market, with chronic bronchitis and drug treatments taking the top spots. Hospitals and clinics were the key end users. Looking ahead, Asia Pacific and oxygen therapy are expected to see the fastest growth.
Last Updated : 04 August 2026Category: Therapeutic AreaInsight Code: 5154Format: PDF / PPT / Excel
Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
Emphysema
Chronic Bronchitis
Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
Drugs
Bronchodilator Monotherapy
Short-Acting Beta2-Agonists (SABAs)
Long-Acting Beta2-Agonists (LABAs)
Anti-Inflammatory Drugs
Oral And Inhaled Corticosteroids
Anti-Leukotrienes
Surgery
Lung Volume Reduction Surgery (LVRS)
Lung Transplant
Bullectomy
Others
Oxygen Therapy
Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
Hospitals & Clinics
Homecare Settings
Others
Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
China
Japan
India
South Korea
Rest of Asia-Pacific
Rest of the World Chronic Obstructive Pulmonary Disease Market Assessment
Overview
Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
Emphysema
Chronic Bronchitis
Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
Drugs
Bronchodilator Monotherapy
Short-Acting Beta2-Agonists (SABAs)
Long-Acting Beta2-Agonists (LABAs)
Anti-Inflammatory Drugs
Oral And Inhaled Corticosteroids
Anti-Leukotrienes
Surgery
Lung Volume Reduction Surgery (LVRS)
Lung Transplant
Bullectomy
Others
Oxygen Therapy
Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
Hospitals & Clinics
Homecare Settings
Others
Company Profiles
Almirall
Company Overview
Geographic Footprints
Financial Performance
Product Portfolio
SWOT Analysis
R&D Efforts
Recent Developments & Strategic Collaborations
Product Launch/M&A/Technical Collaboration
Abbott Laboratories
Dr. Reddy’s Laboratories Ltd.
AstraZeneca
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline
Boehringer Ingelheim
Pfizer Inc.
Astellas Pharma
Novartis AG
Merck & Co., Inc.
Conclusion & Recommendations
FAQ's
Answer : The COPD market is expected to grow from USD 23.55 billion in 2025 to USD 36.29 billion by 2035, registering a steady CAGR of 4.42% driven by rising disease prevalence and long-term treatment demand.
Answer : North America leads the market due to high COPD prevalence, strong healthcare infrastructure, early diagnosis initiatives, high treatment adoption, and substantial healthcare spending in the U.S. and Canada.
Answer : Major companies such as AstraZeneca, GSK, Pfizer, Novartis, Merck & Co., Roche, and Boehringer Ingelheim are driving market innovation through robust pipelines, biologics, and next-generation inhaled therapies.
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare
market research. As a content reviewer, Aditi ensures the quality and accuracy of all market
insights and data presented by the research team.
We use cookies that are necessary to make our site work. We may also use additional cookies to analyze,
improve, and personalize our content and your digital experience.
You can manage your cookie preferences using the
Privacy Policy
For more information, see our
Terms and Conditions
.
Cookie Preference Center
We use cookies which are necessary to make our site work.
We may also use additional cookies to analyze, improve and personalize
our content and your digital experience.
For more information, please read our
Cookie Policy
.
You may choose not to allow some types of cookies.
Blocking some cookies may impact your experience of the site.
sales@towardshealthcare.com
+1 804-441-9344
Download Sample
USA : +1 8044 419344
sales@towardshealthcare.com